Downregulation of type III interferons in patients with severe COVID-19.
Adult
Aged
C-Reactive Protein
/ analysis
COVID-19
/ blood
Chemokines
/ blood
Down-Regulation
Female
Ferritins
/ blood
Fibrin Fibrinogen Degradation Products
/ analysis
Fibrinogen
/ analysis
Humans
Interferons
/ biosynthesis
Interleukins
/ blood
L-Lactate Dehydrogenase
/ blood
Male
Middle Aged
Mucin-1
/ blood
Pulmonary Surfactant-Associated Protein A
/ blood
Pulmonary Surfactant-Associated Protein D
/ blood
SARS-CoV-2
/ immunology
Severity of Illness Index
Interferon Lambda
COVID-19
IFN-lambda
SARS-CoV-2
chemokine
cytokine
type III interferon
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
25
03
2021
received:
04
02
2021
accepted:
30
03
2021
pubmed:
4
4
2021
medline:
9
6
2021
entrez:
3
4
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is globally rampant, and to curb the growing burden of this disease, in-depth knowledge about its pathophysiology is needed. This was an observational study conducted at a single center to investigate serum cytokine and chemokine levels of COVID-19 patients, based on disease severity. We included 72 consecutive COVID-19 patients admitted to our hospital from March 21 to August 31, 2020. Patients were divided into Mild-Moderate I (mild) and Moderate II-Severe (severe) groups based on the COVID-19 severity classification developed by the Ministry of Health, Labor and Welfare (MHLW) of Japan. We compared the patient characteristics as well as the serum cytokine and chemokine levels on the day of admission between the two groups. Our findings indicated that the severe group had significantly higher levels of serum fibrinogen, d-dimer, lactate dehydrogenase, C-reactive protein, ferritin, Krebs von den Lungen-6, surfactant protein (SP)-D, and SP-A than the mild group. Strikingly, the levels of interleukin (IL)-28A/interferon (IFN)-λ2 were significantly lower in the severe group than in the mild group. We believe that reduced levels of type III interferons (IFN-λs) and alterations in the levels of other cytokines and chemokines may impact the severity of the disease.
Identifiants
pubmed: 33811680
doi: 10.1002/jmv.26993
pmc: PMC8250710
doi:
Substances chimiques
Chemokines
0
Fibrin Fibrinogen Degradation Products
0
interferon-lambda, human
0
Interleukins
0
MUC1 protein, human
0
Mucin-1
0
Pulmonary Surfactant-Associated Protein A
0
Pulmonary Surfactant-Associated Protein D
0
fibrin fragment D
0
Fibrinogen
9001-32-5
C-Reactive Protein
9007-41-4
Ferritins
9007-73-2
Interferons
9008-11-1
L-Lactate Dehydrogenase
EC 1.1.1.27
Interferon Lambda
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4559-4563Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K10654
Organisme : Japan Society for the Promotion of Science
ID : 18K16160
Organisme : Japan Society for the Promotion of Science
ID : 19K24240
Organisme : Japan Society for the Promotion of Science
ID : 20K03161
Organisme : Environmental Restoration and Conservation Agency
ID : 2019 to 2021
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
J Thorac Dis. 2020 May;12(5):1781-1798
pubmed: 32642084
J Med Virol. 2021 Jul;93(7):4559-4563
pubmed: 33811680
Nat Med. 2006 Sep;12(9):1023-6
pubmed: 16906156
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Curr Opin Immunol. 2019 Feb;56:67-75
pubmed: 30399529
J Virol. 2020 Sep 15;94(19):
pubmed: 32699094
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
J Biol Chem. 2020 Oct 9;295(41):13958-13964
pubmed: 32587093
BMJ. 2021 Jan 20;372:n84
pubmed: 33472855
Physiol Rep. 2021 Feb;9(4):e14761
pubmed: 33625796
Nature. 2020 Oct;586(7830):560-566
pubmed: 32854108
JAMA Intern Med. 2021 Jan 1;181(1):32-40
pubmed: 33080017
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
Nat Immunol. 2003 Jan;4(1):69-77
pubmed: 12483210
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
Am J Respir Cell Mol Biol. 2017 Feb;56(2):202-212
pubmed: 27632156